Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types.
Pashtoon Murtaza KasiJessica K LeeLincoln W PasquinaBrennan DeckerPierre Vanden BorreDean C PavlickJustin M AllenChristine ParachoniakJulia Coelho França QuintanilhaRyon P GrafAlexa B SchrockGeoffrey R OxnardChristine M LovlyHanna TukachinskyVivek SubbiahPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In contrast to some prior literature, this study reports detection of a wide variety of rearrangements in ctDNA. The prevalence of driver rearrangements in tissue and LBx was comparable when TF ≥1%. LBx presents a viable alternative when TBx is not available, and there may be less value in confirmatory testing when TF is sufficient.